BIOMARIN PHARMACEUTICAL INC 8-K

What Happened
BioMarin Pharmaceutical Inc. presented a business update at the J.P. Morgan Healthcare Conference on January 12, 2026 and filed an 8‑K disclosing preliminary, unaudited financial results for the year ended December 31, 2025. The company estimates total 2025 revenues of approximately $3.2 billion, including about $920 million from VOXZOGO® sales. BioMarin also expects to record an asset write‑down related to ROCTAVIAN in Q4 2025 of roughly $230–$260 million; about $120–$125 million (or $(0.60)–$(0.64) per share, assuming ~200 million diluted shares) is expected to reduce Non‑GAAP Income and Non‑GAAP Diluted EPS for 2025. Excluding this write‑down, BioMarin says its previously issued 2025 full‑year Non‑GAAP Diluted EPS guidance (from October 27, 2025) remains unchanged.

Key Details

• Preliminary total 2025 revenue: ~ $3.2 billion (unaudited).
• VOXZOGO® 2025 revenue: ~ $920 million (unaudited).
• Expected ROCTAVIAN asset write‑down (Q4 2025): $230–$260 million; ~$120–$125M reduces Non‑GAAP Income ($(0.60)–$(0.64) per share, assuming ~200M diluted shares).
• Results are preliminary and unaudited; subject to completion of year‑end accounting and closing procedures.

Why It Matters
Investors should note the company still expects strong revenue (notably VOXZOGO sales) but will take a sizable ROCTAVIAN write‑down that materially lowers reported Non‑GAAP earnings per share for 2025. The figures are preliminary and may change after final accounting close. BioMarin also emphasizes its use of Non‑GAAP measures and warns these differ from GAAP metrics, so investors should review the final audited results and the company’s SEC filings for complete detail.